Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)

@article{Buesa1998PhaseIT,
  title={Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)},
  author={Jos{\'e} Mar{\'i}a Buesa and Antonio L{\'o}pez-pousa and Javier Mart{\'i}n and Antonio J. Monroy Ant{\'o}n and Javier Garc{\'i}a del Muro and Joaquin Bellmunt and Francisco Javier Plaza Arranz and Vicente Valent{\'i} and Pilar Escudero and David Menendez and Antonio Cuevas Casado and Andr{\'e}s M Poveda},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1998},
  volume={9 8},
  pages={871-6}
}
BACKGROUND The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i.e., doses > 10 g/m2), which supports a dose-response relationship for this drug. Because of a lack of first-line studies in adult STS patients, we decided to test the activity and toxicity of HDI in a phase II trial. PATIENTS AND METHODS Forty-eight patients were enrolled in the study. IFOS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information

Annals of oncology : official journal of the European Society for Medical Oncology • 2011
View 14 Excerpts
Highly Influenced

Single-institution, multidisciplinary experience with surgical resection of primary chest wall sarcomas.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2012

Similar Papers

Loading similar papers…